Literature DB >> 24041831

Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM).

Arada Rojana-udomsart1, Chalermchai Mitrpant, Christine Bundell, Loren Price, Yue-Bei Luo, Victoria Fabian, Steve D Wilton, Peter Hollingsworth, Frank L Mastaglia.   

Abstract

The mechanism of necrotizing myopathy associated with antibodies to signal recognition particle (SRP) remains unclear. We investigated the effect of anti-SRP+serum and complement on cell viability in myoblast cultures. Cell viability was only slightly reduced by incubation with anti-SRP+serum compared with control serum. However, the addition of fresh complement resulted in a marked reduction in cell survival. Surface immunostaining for SRP, C3c and C5b-9 was demonstrated in cultures pre-incubated with anti-SRP+serum and complement, and in muscle biopsies from patients with myopathy. These findings provide further support for a complement-dependent antibody-mediated mechanism in anti-SRP associated myopathy.
© 2013.

Entities:  

Keywords:  Anti-SRP antibody; Complement mediated cell lysis; Necrotizing myopathy

Mesh：

Substances：

Year:  2013        PMID： 24041831     DOI： 10.1016/j.jneuroim.2013.08.008

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN： 0165-5728            Impact factor:   3.478


  9 in total

1.  The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy.

Authors:  Tae Chung; Lisa Christopher-Stine; Julie J Paik; Andrea Corse; Andrew L Mammen
Journal:  Muscle Nerve       Date:  2015-05-14       Impact factor: 3.217

2.  Cardiac troponin T and autoimmunity in skeletal muscle aging.

Authors:  Tan Zhang; Xin Feng; Juan Dong; Zherong Xu; Bo Feng; Karen M Haas; Peggy M Cawthon; Kristen M Beavers; Barbara Nicklas; Stephen Kritchevsky
Journal:  Geroscience       Date:  2022-01-15       Impact factor: 7.581

Review 3.  Potential Pathogenic Role of Anti-Signal Recognition Protein and Anti-3-hydroxy-3-methylglutaryl-CoA Reductase Antibodies in Immune-Mediated Necrotizing Myopathies.

Authors:  Leandro Ladislau; Louiza Arouche-Delaperche; Yves Allenbach; Olivier Benveniste
Journal:  Curr Rheumatol Rep       Date:  2018-08-03       Impact factor: 4.592

4.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

Review 5.  Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications.

Authors:  E M Moran; F L Mastaglia
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 6.  Immunotherapies for Immune-Mediated Myopathies: A Current Perspective.

Authors:  Merrilee Needham; Frank L Mastaglia
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 7.  Belimumab for Immune-Mediated Necrotizing Myopathy Associated With Anti-SRP Antibodies: A Case Report and Retrospective Review of Patients Treated With Anti-B-Cell Therapy in a Single Center and Literature.

Authors:  Bei-Bei Cui; Yun-Ru Tian; Xin-Yue Ma; Geng Yin; Qibing Xie
Journal:  Front Immunol       Date:  2021-12-02       Impact factor: 7.561

8.  A Rare Case of Anti-HMGCR and Anti-SRP-Positive Immune-Mediated Necrotizing Myopathy.

Authors:  Nariman Khan; Zehra Kazmi
Journal:  Qatar Med J       Date:  2022-02-22

Review 9.  Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review.

Authors:  Renske G Kamperman; Anneke J van der Kooi; Marianne de Visser; Eleonora Aronica; Joost Raaphorst
Journal:  Int J Mol Sci       Date:  2022-04-13       Impact factor: 6.208
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.